Literature DB >> 21245574

KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.

Lynn M Hassman1, Thomas J Ellison, Dean H Kedes.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV; also known as HHV8) is the causative agent of two B cell tumors, multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL). However, little is known about the nature of the specific B cell subtype(s) most susceptible to infection. Identifying these cells would provide direct insight into KSHV transmission and virus-induced transformation. To identify this subset and to determine whether infection alters its cellular phenotype, we exposed human tonsillar cells to KSHV and characterized infected cells using high-throughput multispectral imaging flow cytometry (MIFC). Stable expression of the virally encoded latency-associated nuclear antigen (LANA), a marker of latent KSHV infection, was observed predominantly in cells expressing the l light chain of the B cell receptor. These LANA+ B cells proliferated and exhibited similarities to the cells characteristic of MCD (IgMl-expressing plasmablasts), including blasting morphology with elevated expression of Ki67, variable expression of CD27, and high levels of IgM and IL-6 receptor. Furthermore, the proportion of infected cells showing a blasting phenotype increased upon addition of exogenous IL-6. Our data lead us to propose that oral transmission of KSHV involves the latent infection of a subset of tonsillar IgMl-expressing B cells, which then proliferate as they acquire the plasmablast phenotype characteristic of MCD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245574      PMCID: PMC3026728          DOI: 10.1172/JCI44185

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

1.  Extended depth of field imaging for high speed cell analysis.

Authors:  William E Ortyn; David J Perry; Vidya Venkatachalam; Luchuan Liang; Brian E Hall; Keith Frost; David A Basiji
Journal:  Cytometry A       Date:  2007-04       Impact factor: 4.355

2.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

3.  Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen.

Authors:  G Gaidano; A Gloghini; V Gattei; M F Rossi; A M Cilia; C Godeas; M Degan; T Perin; V Canzonieri; D Aldinucci; G Saglio; A Carbone; A Pinto
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

4.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

5.  Detection of herpesvirus type 8 (HHV8) in children's tonsils and adenoids by immunohistochemistry and in situ hybridization.

Authors:  Cristiano Aparecido Chagas; Luiza Hayashi Endo; Eulália Sakano; Glauce Aparecida Pinto; Pierre Brousset; José Vassallo
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2005-06-23       Impact factor: 1.675

6.  Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

Authors:  Karin Tarte; John De Vos; Thomas Thykjaer; Fenghuang Zhan; Geneviève Fiol; Valérie Costes; Thierry Rème; Eric Legouffe; Jean-François Rossi; John Shaughnessy; Torben F Ørntoft; Bernard Klein
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

7.  B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Fuqu Yu; Jiaying Feng; Josephine N Harada; Sumit K Chanda; Shannon C Kenney; Ren Sun
Journal:  FEBS Lett       Date:  2007-06-29       Impact factor: 4.124

Review 8.  A mouse model for infectious mononucleosis.

Authors:  Emilio Flaño; David L Woodland; Marcia A Blackman
Journal:  Immunol Res       Date:  2002       Impact factor: 4.505

9.  KSHV manipulates Notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endothelia.

Authors:  Victoria Emuss; Dimitrios Lagos; Arnold Pizzey; Fiona Gratrix; Stephen R Henderson; Chris Boshoff
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

10.  Isolation and characterization of human tonsil dendritic cells.

Authors:  D N Hart; J L McKenzie
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more
  60 in total

1.  KSHV infection of B-cell lymphoma using a modified KSHV BAC36 and coculturing system.

Authors:  Hyosun Cho; Hyojeung Kang
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

2.  A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice.

Authors:  Isaac W Boss; Peter E Nadeau; Jeffrey R Abbott; Yajie Yang; Ayalew Mergia; Rolf Renne
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.

Authors:  Lisa Steinbrück; Montse Gustems; Stephanie Medele; Thomas F Schulz; Dominik Lutter; Wolfgang Hammerschmidt
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

4.  Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease.

Authors:  Pierre Arnautou; Martine Auclair; Soraya Fellahi; Clara Bouché; Claire Fieschi; Elias Barrak; Viviane Queyrel-Moranne; Lucy Chaillous; Nicolas Blin; Marion Malphettes; Jehane Fadlallah; Remi Bertinchamp; Laurence Gérard; Djaouida Bengoufa; Lionel Galicier; Eric Oksenhendler; Corinne Vigouroux; David Boutboul
Journal:  Blood Adv       Date:  2021-04-13

5.  Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity.

Authors:  Stephen J Dollery; Rey J Santiago-Crespo; Deboeeta Chatterjee; Edward A Berger
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.

Authors:  Ciaren Graham; Hittu Matta; Yanqiang Yang; Han Yi; Yulan Suo; Bhairavi Tolani; Preet M Chaudhary
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

7.  Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells.

Authors:  Adriana Forero; Kevin D McCormick; Frank J Jenkins; Saumendra N Sarkar
Journal:  Virology       Date:  2014-05-05       Impact factor: 3.616

8.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

9.  Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.

Authors:  Semra Kati; Edward H Tsao; Thomas Günther; Magdalena Weidner-Glunde; Thomas Rothämel; Adam Grundhoff; Paul Kellam; Thomas F Schulz
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  Tracking expression and subcellular localization of RNA and protein species using high-throughput single cell imaging flow cytometry.

Authors:  Sumit Borah; Lisa A Nichols; Lynn M Hassman; Dean H Kedes; Joan A Steitz
Journal:  RNA       Date:  2012-06-28       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.